Edgewise Therapeutics EWTX
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
Key Insights
Edgewise Therapeutics (EWTX) Core Market Data and Business Metrics
Latest Closing Price
$15.52Price-Earnings Ratio
-10.35Total Outstanding Shares
95.21 Million SharesDividend
No dividendSIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQHeadquarters
1715 38th St, Boulder, CO, 80301
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Short Interest
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
| Avg Daily Volume | Days to Cover | Settlement Date | Short Interest |
|---|---|---|---|
| 1,551,233 Shares | 5.86 | 3/14/2025 | 9,088,389 Shares |
| 1,117,912 Shares | 7.81 | 2/28/2025 | 8,732,881 Shares |
| 940,526 Shares | 8.57 | 2/14/2025 | 8,057,846 Shares |
| 866,242 Shares | 8.15 | 1/31/2025 | 7,055,664 Shares |
| 1,006,915 Shares | 6.69 | 1/15/2025 | 6,736,305 Shares |
| 1,088,980 Shares | 5.64 | 12/31/2024 | 6,141,675 Shares |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Operating Activities | $-108.90 Million |
| Net Cash Flow From Financing Activities | $299.35 Million |
| Net Cash Flow | $11.85 Million |
| Net Cash Flow From Investing Activities, Continuing | $-178.59 Million |
| Net Cash Flow, Continuing | $11.85 Million |
| Net Cash Flow From Financing Activities, Continuing | $299.35 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Operating Expenses | $147.15 Million |
| Operating Income/Loss | $-147.15 Million |
| Basic Average Shares | $91.99 Million |
| Diluted Average Shares | $91.99 Million |
| Preferred Stock Dividends And Other Adjustments | $0 |
| Revenues | $0 |
Comprehensive Income
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Parent | $-122.82 Million |
| Other Comprehensive Income/Loss | $1.48 Million |
| Comprehensive Income/Loss | $-122.82 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Equity Attributable To Parent | $488.88 Million |
| Liabilities | $22.41 Million |
| Liabilities And Equity | $511.28 Million |
| Equity Attributable To Noncontrolling Interest | $0 |
| Assets | $511.28 Million |
| Other Non-current Assets | $1.88 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||